Global Microbiome Therapeutics Supply, Demand and Key Producers, 2026-2032
The global Microbiome Therapeutics market size is expected to reach $ 4251 million by 2032, rising at a market growth of 29.8% CAGR during the forecast period (2026-2032).
Microbiome Therapeutics refers to novel therapeutic approaches that utilize modulation of the human microbiome—especially gut microbiota—to treat or prevent diseases. These therapies include live biotherapeutic products (LBPs), fecal microbiota transplantation (FMT), engineered bacteria, and microbiota-derived metabolites aimed at rebalancing microbial ecosystems. They are being developed for a wide range of conditions, including metabolic disorders, immune dysfunction, neurological diseases, inflammatory bowel disease (IBD), and as adjuncts to cancer immunotherapy. Compared to traditional pharmaceuticals, microbiome-based therapies offer high specificity, personalization, and long-term safety, making them the “fourth therapeutic modality” following small molecules, biologics, and cell/gene therapies.
As the global push for personalized medicine, chronic disease management, and immune-oncology adjunct therapies gains momentum, microbiome therapeutics is entering a critical commercialization window. Regulatory agencies such as the FDA and EMA are streamlining approval pathways for live biotherapeutic products (LBPs), while landmark approvals of Rebyota and Vowst mark a turning point. Strategic alliances between biotech startups and global pharma are accelerating late-stage clinical programs, supported by both capital and platform synergies.
Despite its transformative potential, the microbiome therapeutics sector faces multiple uncertainties. Manufacturing and regulatory frameworks remain inconsistent across countries, slowing clinical translation. Microbiota therapies face inherent variability and complexity, posing challenges in standardizing efficacy and trial design. Technical bottlenecks in sample sourcing, cold-chain logistics, and microbial viability maintenance elevate development costs. Additionally, market education and patient acceptance still require time, particularly in emerging regions like Asia, where applications are largely limited to early-stage R&D and clinical trials.
Demand is expanding beyond gastrointestinal conditions into systemic diseases such as IBD, recurrent Clostridioides difficile infection (CDI), cancer immunotherapy, Parkinson’s, and autism spectrum disorders. Partnerships between CROs and pharma are intensifying, while genomics, metabolomics, and AI are enabling high-throughput microbial strain screening. The clinical sector is seeking more reproducible, orally deliverable LBPs and microbiome-derived metabolite products, which align with industrial scalability. With public and private insurers beginning to cover these new modalities, microbiome therapeutics is on the path to becoming a standard pillar of precision medicine.
This report studies the global Microbiome Therapeutics demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Microbiome Therapeutics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Microbiome Therapeutics that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Microbiome Therapeutics total market, 2021-2032, (USD Million)
Global Microbiome Therapeutics total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Microbiome Therapeutics total market, key domestic companies, and share, (USD Million)
Global Microbiome Therapeutics revenue by player, revenue and market share 2021-2026, (USD Million)
Global Microbiome Therapeutics total market by Type, CAGR, 2021-2032, (USD Million)
Global Microbiome Therapeutics total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Microbiome Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Finch Therapeutics, PureTech, Synlogic, Enterome BioScience, 4D Pharma, Second Genome, Ferring, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Microbiome Therapeutics market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Microbiome Therapeutics Market, By Region:
1. How big is the global Microbiome Therapeutics market?
2. What is the demand of the global Microbiome Therapeutics market?
3. What is the year over year growth of the global Microbiome Therapeutics market?
4. What is the total value of the global Microbiome Therapeutics market?
5. Who are the Major Players in the global Microbiome Therapeutics market?
6. What are the growth factors driving the market demand?
Microbiome Therapeutics refers to novel therapeutic approaches that utilize modulation of the human microbiome—especially gut microbiota—to treat or prevent diseases. These therapies include live biotherapeutic products (LBPs), fecal microbiota transplantation (FMT), engineered bacteria, and microbiota-derived metabolites aimed at rebalancing microbial ecosystems. They are being developed for a wide range of conditions, including metabolic disorders, immune dysfunction, neurological diseases, inflammatory bowel disease (IBD), and as adjuncts to cancer immunotherapy. Compared to traditional pharmaceuticals, microbiome-based therapies offer high specificity, personalization, and long-term safety, making them the “fourth therapeutic modality” following small molecules, biologics, and cell/gene therapies.
As the global push for personalized medicine, chronic disease management, and immune-oncology adjunct therapies gains momentum, microbiome therapeutics is entering a critical commercialization window. Regulatory agencies such as the FDA and EMA are streamlining approval pathways for live biotherapeutic products (LBPs), while landmark approvals of Rebyota and Vowst mark a turning point. Strategic alliances between biotech startups and global pharma are accelerating late-stage clinical programs, supported by both capital and platform synergies.
Despite its transformative potential, the microbiome therapeutics sector faces multiple uncertainties. Manufacturing and regulatory frameworks remain inconsistent across countries, slowing clinical translation. Microbiota therapies face inherent variability and complexity, posing challenges in standardizing efficacy and trial design. Technical bottlenecks in sample sourcing, cold-chain logistics, and microbial viability maintenance elevate development costs. Additionally, market education and patient acceptance still require time, particularly in emerging regions like Asia, where applications are largely limited to early-stage R&D and clinical trials.
Demand is expanding beyond gastrointestinal conditions into systemic diseases such as IBD, recurrent Clostridioides difficile infection (CDI), cancer immunotherapy, Parkinson’s, and autism spectrum disorders. Partnerships between CROs and pharma are intensifying, while genomics, metabolomics, and AI are enabling high-throughput microbial strain screening. The clinical sector is seeking more reproducible, orally deliverable LBPs and microbiome-derived metabolite products, which align with industrial scalability. With public and private insurers beginning to cover these new modalities, microbiome therapeutics is on the path to becoming a standard pillar of precision medicine.
This report studies the global Microbiome Therapeutics demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Microbiome Therapeutics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Microbiome Therapeutics that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Microbiome Therapeutics total market, 2021-2032, (USD Million)
Global Microbiome Therapeutics total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Microbiome Therapeutics total market, key domestic companies, and share, (USD Million)
Global Microbiome Therapeutics revenue by player, revenue and market share 2021-2026, (USD Million)
Global Microbiome Therapeutics total market by Type, CAGR, 2021-2032, (USD Million)
Global Microbiome Therapeutics total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Microbiome Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Finch Therapeutics, PureTech, Synlogic, Enterome BioScience, 4D Pharma, Second Genome, Ferring, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Microbiome Therapeutics market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Microbiome Therapeutics Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Upper GIT
- Lower GIT
- C. difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Orphan Drug
- Immuno-oncology
- Others
- Seres Therapeutics
- Assembly Biosciences
- Synthetic Biologics
- Finch Therapeutics
- PureTech
- Synlogic
- Enterome BioScience
- 4D Pharma
- Second Genome
- Ferring
- C3 Jian
- Rebiotix
- MicroBiome Therapeutics LLC
- Metabiomics
- Ritter Pharmaceuticals
- Symberix
- OpenBiome
- Azitra
- Symbiotix Biotherapies
- Vedanta Biosciences
- Metabogen
1. How big is the global Microbiome Therapeutics market?
2. What is the demand of the global Microbiome Therapeutics market?
3. What is the year over year growth of the global Microbiome Therapeutics market?
4. What is the total value of the global Microbiome Therapeutics market?
5. Who are the Major Players in the global Microbiome Therapeutics market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Microbiome Therapeutics Introduction
1.2 World Microbiome Therapeutics Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Microbiome Therapeutics Total Market by Region (by Headquarter Location)
1.3.1 World Microbiome Therapeutics Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Microbiome Therapeutics Revenue (2021-2032)
1.3.3 China Based Company Microbiome Therapeutics Revenue (2021-2032)
1.3.4 Europe Based Company Microbiome Therapeutics Revenue (2021-2032)
1.3.5 Japan Based Company Microbiome Therapeutics Revenue (2021-2032)
1.3.6 South Korea Based Company Microbiome Therapeutics Revenue (2021-2032)
1.3.7 ASEAN Based Company Microbiome Therapeutics Revenue (2021-2032)
1.3.8 India Based Company Microbiome Therapeutics Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Microbiome Therapeutics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Microbiome Therapeutics Consumption Value (2021-2032)
2.2 World Microbiome Therapeutics Consumption Value by Region
2.2.1 World Microbiome Therapeutics Consumption Value by Region (2021-2026)
2.2.2 World Microbiome Therapeutics Consumption Value Forecast by Region (2027-2032)
2.3 United States Microbiome Therapeutics Consumption Value (2021-2032)
2.4 China Microbiome Therapeutics Consumption Value (2021-2032)
2.5 Europe Microbiome Therapeutics Consumption Value (2021-2032)
2.6 Japan Microbiome Therapeutics Consumption Value (2021-2032)
2.7 South Korea Microbiome Therapeutics Consumption Value (2021-2032)
2.8 ASEAN Microbiome Therapeutics Consumption Value (2021-2032)
2.9 India Microbiome Therapeutics Consumption Value (2021-2032)
3 WORLD MICROBIOME THERAPEUTICS COMPANIES COMPETITIVE ANALYSIS
3.1 World Microbiome Therapeutics Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Microbiome Therapeutics Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Microbiome Therapeutics in 2025
3.2.3 Global Concentration Ratios (CR8) for Microbiome Therapeutics in 2025
3.3 Microbiome Therapeutics Company Evaluation Quadrant
3.4 Microbiome Therapeutics Market: Overall Company Footprint Analysis
3.4.1 Microbiome Therapeutics Market: Region Footprint
3.4.2 Microbiome Therapeutics Market: Company Product Type Footprint
3.4.3 Microbiome Therapeutics Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Microbiome Therapeutics Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Microbiome Therapeutics Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Microbiome Therapeutics Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Microbiome Therapeutics Consumption Value Comparison
4.2.1 United States VS China: Microbiome Therapeutics Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Microbiome Therapeutics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Microbiome Therapeutics Companies and Market Share, 2021-2026
4.3.1 United States Based Microbiome Therapeutics Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Microbiome Therapeutics Revenue, (2021-2026)
4.4 China Based Companies Microbiome Therapeutics Revenue and Market Share, 2021-2026
4.4.1 China Based Microbiome Therapeutics Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Microbiome Therapeutics Revenue, (2021-2026)
4.5 Rest of World Based Microbiome Therapeutics Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Microbiome Therapeutics Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Microbiome Therapeutics Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Microbiome Therapeutics Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Upper GIT
5.2.2 Lower GIT
5.3 Market Segment by Type
5.3.1 World Microbiome Therapeutics Market Size by Type (2021-2026)
5.3.2 World Microbiome Therapeutics Market Size by Type (2027-2032)
5.3.3 World Microbiome Therapeutics Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Microbiome Therapeutics Market Size Overview by Application: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Application
6.2.1 C. difficile Infection (CDI)
6.2.2 Inflammatory Bowel Disease (IBD)
6.2.3 Orphan Drug
6.2.4 Immuno-oncology
6.2.5 Others
6.3 Market Segment by Application
6.3.1 World Microbiome Therapeutics Market Size by Application (2021-2026)
6.3.2 World Microbiome Therapeutics Market Size by Application (2027-2032)
6.3.3 World Microbiome Therapeutics Market Size Market Share by Application (2021-2032)
7 COMPANY PROFILES
7.1 Seres Therapeutics
7.1.1 Seres Therapeutics Details
7.1.2 Seres Therapeutics Major Business
7.1.3 Seres Therapeutics Microbiome Therapeutics Product and Services
7.1.4 Seres Therapeutics Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.1.5 Seres Therapeutics Recent Developments/Updates
7.1.6 Seres Therapeutics Competitive Strengths & Weaknesses
7.2 Assembly Biosciences
7.2.1 Assembly Biosciences Details
7.2.2 Assembly Biosciences Major Business
7.2.3 Assembly Biosciences Microbiome Therapeutics Product and Services
7.2.4 Assembly Biosciences Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.2.5 Assembly Biosciences Recent Developments/Updates
7.2.6 Assembly Biosciences Competitive Strengths & Weaknesses
7.3 Synthetic Biologics
7.3.1 Synthetic Biologics Details
7.3.2 Synthetic Biologics Major Business
7.3.3 Synthetic Biologics Microbiome Therapeutics Product and Services
7.3.4 Synthetic Biologics Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.3.5 Synthetic Biologics Recent Developments/Updates
7.3.6 Synthetic Biologics Competitive Strengths & Weaknesses
7.4 Finch Therapeutics
7.4.1 Finch Therapeutics Details
7.4.2 Finch Therapeutics Major Business
7.4.3 Finch Therapeutics Microbiome Therapeutics Product and Services
7.4.4 Finch Therapeutics Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.4.5 Finch Therapeutics Recent Developments/Updates
7.4.6 Finch Therapeutics Competitive Strengths & Weaknesses
7.5 PureTech
7.5.1 PureTech Details
7.5.2 PureTech Major Business
7.5.3 PureTech Microbiome Therapeutics Product and Services
7.5.4 PureTech Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.5.5 PureTech Recent Developments/Updates
7.5.6 PureTech Competitive Strengths & Weaknesses
7.6 Synlogic
7.6.1 Synlogic Details
7.6.2 Synlogic Major Business
7.6.3 Synlogic Microbiome Therapeutics Product and Services
7.6.4 Synlogic Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.6.5 Synlogic Recent Developments/Updates
7.6.6 Synlogic Competitive Strengths & Weaknesses
7.7 Enterome BioScience
7.7.1 Enterome BioScience Details
7.7.2 Enterome BioScience Major Business
7.7.3 Enterome BioScience Microbiome Therapeutics Product and Services
7.7.4 Enterome BioScience Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.7.5 Enterome BioScience Recent Developments/Updates
7.7.6 Enterome BioScience Competitive Strengths & Weaknesses
7.8 4D Pharma
7.8.1 4D Pharma Details
7.8.2 4D Pharma Major Business
7.8.3 4D Pharma Microbiome Therapeutics Product and Services
7.8.4 4D Pharma Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.8.5 4D Pharma Recent Developments/Updates
7.8.6 4D Pharma Competitive Strengths & Weaknesses
7.9 Second Genome
7.9.1 Second Genome Details
7.9.2 Second Genome Major Business
7.9.3 Second Genome Microbiome Therapeutics Product and Services
7.9.4 Second Genome Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.9.5 Second Genome Recent Developments/Updates
7.9.6 Second Genome Competitive Strengths & Weaknesses
7.10 Ferring
7.10.1 Ferring Details
7.10.2 Ferring Major Business
7.10.3 Ferring Microbiome Therapeutics Product and Services
7.10.4 Ferring Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.10.5 Ferring Recent Developments/Updates
7.10.6 Ferring Competitive Strengths & Weaknesses
7.11 C3 Jian
7.11.1 C3 Jian Details
7.11.2 C3 Jian Major Business
7.11.3 C3 Jian Microbiome Therapeutics Product and Services
7.11.4 C3 Jian Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.11.5 C3 Jian Recent Developments/Updates
7.11.6 C3 Jian Competitive Strengths & Weaknesses
7.12 Rebiotix
7.12.1 Rebiotix Details
7.12.2 Rebiotix Major Business
7.12.3 Rebiotix Microbiome Therapeutics Product and Services
7.12.4 Rebiotix Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.12.5 Rebiotix Recent Developments/Updates
7.12.6 Rebiotix Competitive Strengths & Weaknesses
7.13 MicroBiome Therapeutics LLC
7.13.1 MicroBiome Therapeutics LLC Details
7.13.2 MicroBiome Therapeutics LLC Major Business
7.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Product and Services
7.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.13.5 MicroBiome Therapeutics LLC Recent Developments/Updates
7.13.6 MicroBiome Therapeutics LLC Competitive Strengths & Weaknesses
7.14 Metabiomics
7.14.1 Metabiomics Details
7.14.2 Metabiomics Major Business
7.14.3 Metabiomics Microbiome Therapeutics Product and Services
7.14.4 Metabiomics Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.14.5 Metabiomics Recent Developments/Updates
7.14.6 Metabiomics Competitive Strengths & Weaknesses
7.15 Ritter Pharmaceuticals
7.15.1 Ritter Pharmaceuticals Details
7.15.2 Ritter Pharmaceuticals Major Business
7.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Product and Services
7.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.15.5 Ritter Pharmaceuticals Recent Developments/Updates
7.15.6 Ritter Pharmaceuticals Competitive Strengths & Weaknesses
7.16 Symberix
7.16.1 Symberix Details
7.16.2 Symberix Major Business
7.16.3 Symberix Microbiome Therapeutics Product and Services
7.16.4 Symberix Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.16.5 Symberix Recent Developments/Updates
7.16.6 Symberix Competitive Strengths & Weaknesses
7.17 OpenBiome
7.17.1 OpenBiome Details
7.17.2 OpenBiome Major Business
7.17.3 OpenBiome Microbiome Therapeutics Product and Services
7.17.4 OpenBiome Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.17.5 OpenBiome Recent Developments/Updates
7.17.6 OpenBiome Competitive Strengths & Weaknesses
7.18 Azitra
7.18.1 Azitra Details
7.18.2 Azitra Major Business
7.18.3 Azitra Microbiome Therapeutics Product and Services
7.18.4 Azitra Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.18.5 Azitra Recent Developments/Updates
7.18.6 Azitra Competitive Strengths & Weaknesses
7.19 Symbiotix Biotherapies
7.19.1 Symbiotix Biotherapies Details
7.19.2 Symbiotix Biotherapies Major Business
7.19.3 Symbiotix Biotherapies Microbiome Therapeutics Product and Services
7.19.4 Symbiotix Biotherapies Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.19.5 Symbiotix Biotherapies Recent Developments/Updates
7.19.6 Symbiotix Biotherapies Competitive Strengths & Weaknesses
7.20 Vedanta Biosciences
7.20.1 Vedanta Biosciences Details
7.20.2 Vedanta Biosciences Major Business
7.20.3 Vedanta Biosciences Microbiome Therapeutics Product and Services
7.20.4 Vedanta Biosciences Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.20.5 Vedanta Biosciences Recent Developments/Updates
7.20.6 Vedanta Biosciences Competitive Strengths & Weaknesses
7.21 Metabogen
7.21.1 Metabogen Details
7.21.2 Metabogen Major Business
7.21.3 Metabogen Microbiome Therapeutics Product and Services
7.21.4 Metabogen Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.21.5 Metabogen Recent Developments/Updates
7.21.6 Metabogen Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Microbiome Therapeutics Industry Chain
8.2 Microbiome Therapeutics Upstream Analysis
8.3 Microbiome Therapeutics Midstream Analysis
8.4 Microbiome Therapeutics Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Microbiome Therapeutics Introduction
1.2 World Microbiome Therapeutics Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Microbiome Therapeutics Total Market by Region (by Headquarter Location)
1.3.1 World Microbiome Therapeutics Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Microbiome Therapeutics Revenue (2021-2032)
1.3.3 China Based Company Microbiome Therapeutics Revenue (2021-2032)
1.3.4 Europe Based Company Microbiome Therapeutics Revenue (2021-2032)
1.3.5 Japan Based Company Microbiome Therapeutics Revenue (2021-2032)
1.3.6 South Korea Based Company Microbiome Therapeutics Revenue (2021-2032)
1.3.7 ASEAN Based Company Microbiome Therapeutics Revenue (2021-2032)
1.3.8 India Based Company Microbiome Therapeutics Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Microbiome Therapeutics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Microbiome Therapeutics Consumption Value (2021-2032)
2.2 World Microbiome Therapeutics Consumption Value by Region
2.2.1 World Microbiome Therapeutics Consumption Value by Region (2021-2026)
2.2.2 World Microbiome Therapeutics Consumption Value Forecast by Region (2027-2032)
2.3 United States Microbiome Therapeutics Consumption Value (2021-2032)
2.4 China Microbiome Therapeutics Consumption Value (2021-2032)
2.5 Europe Microbiome Therapeutics Consumption Value (2021-2032)
2.6 Japan Microbiome Therapeutics Consumption Value (2021-2032)
2.7 South Korea Microbiome Therapeutics Consumption Value (2021-2032)
2.8 ASEAN Microbiome Therapeutics Consumption Value (2021-2032)
2.9 India Microbiome Therapeutics Consumption Value (2021-2032)
3 WORLD MICROBIOME THERAPEUTICS COMPANIES COMPETITIVE ANALYSIS
3.1 World Microbiome Therapeutics Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Microbiome Therapeutics Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Microbiome Therapeutics in 2025
3.2.3 Global Concentration Ratios (CR8) for Microbiome Therapeutics in 2025
3.3 Microbiome Therapeutics Company Evaluation Quadrant
3.4 Microbiome Therapeutics Market: Overall Company Footprint Analysis
3.4.1 Microbiome Therapeutics Market: Region Footprint
3.4.2 Microbiome Therapeutics Market: Company Product Type Footprint
3.4.3 Microbiome Therapeutics Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Microbiome Therapeutics Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Microbiome Therapeutics Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Microbiome Therapeutics Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Microbiome Therapeutics Consumption Value Comparison
4.2.1 United States VS China: Microbiome Therapeutics Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Microbiome Therapeutics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Microbiome Therapeutics Companies and Market Share, 2021-2026
4.3.1 United States Based Microbiome Therapeutics Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Microbiome Therapeutics Revenue, (2021-2026)
4.4 China Based Companies Microbiome Therapeutics Revenue and Market Share, 2021-2026
4.4.1 China Based Microbiome Therapeutics Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Microbiome Therapeutics Revenue, (2021-2026)
4.5 Rest of World Based Microbiome Therapeutics Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Microbiome Therapeutics Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Microbiome Therapeutics Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Microbiome Therapeutics Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Upper GIT
5.2.2 Lower GIT
5.3 Market Segment by Type
5.3.1 World Microbiome Therapeutics Market Size by Type (2021-2026)
5.3.2 World Microbiome Therapeutics Market Size by Type (2027-2032)
5.3.3 World Microbiome Therapeutics Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Microbiome Therapeutics Market Size Overview by Application: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Application
6.2.1 C. difficile Infection (CDI)
6.2.2 Inflammatory Bowel Disease (IBD)
6.2.3 Orphan Drug
6.2.4 Immuno-oncology
6.2.5 Others
6.3 Market Segment by Application
6.3.1 World Microbiome Therapeutics Market Size by Application (2021-2026)
6.3.2 World Microbiome Therapeutics Market Size by Application (2027-2032)
6.3.3 World Microbiome Therapeutics Market Size Market Share by Application (2021-2032)
7 COMPANY PROFILES
7.1 Seres Therapeutics
7.1.1 Seres Therapeutics Details
7.1.2 Seres Therapeutics Major Business
7.1.3 Seres Therapeutics Microbiome Therapeutics Product and Services
7.1.4 Seres Therapeutics Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.1.5 Seres Therapeutics Recent Developments/Updates
7.1.6 Seres Therapeutics Competitive Strengths & Weaknesses
7.2 Assembly Biosciences
7.2.1 Assembly Biosciences Details
7.2.2 Assembly Biosciences Major Business
7.2.3 Assembly Biosciences Microbiome Therapeutics Product and Services
7.2.4 Assembly Biosciences Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.2.5 Assembly Biosciences Recent Developments/Updates
7.2.6 Assembly Biosciences Competitive Strengths & Weaknesses
7.3 Synthetic Biologics
7.3.1 Synthetic Biologics Details
7.3.2 Synthetic Biologics Major Business
7.3.3 Synthetic Biologics Microbiome Therapeutics Product and Services
7.3.4 Synthetic Biologics Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.3.5 Synthetic Biologics Recent Developments/Updates
7.3.6 Synthetic Biologics Competitive Strengths & Weaknesses
7.4 Finch Therapeutics
7.4.1 Finch Therapeutics Details
7.4.2 Finch Therapeutics Major Business
7.4.3 Finch Therapeutics Microbiome Therapeutics Product and Services
7.4.4 Finch Therapeutics Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.4.5 Finch Therapeutics Recent Developments/Updates
7.4.6 Finch Therapeutics Competitive Strengths & Weaknesses
7.5 PureTech
7.5.1 PureTech Details
7.5.2 PureTech Major Business
7.5.3 PureTech Microbiome Therapeutics Product and Services
7.5.4 PureTech Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.5.5 PureTech Recent Developments/Updates
7.5.6 PureTech Competitive Strengths & Weaknesses
7.6 Synlogic
7.6.1 Synlogic Details
7.6.2 Synlogic Major Business
7.6.3 Synlogic Microbiome Therapeutics Product and Services
7.6.4 Synlogic Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.6.5 Synlogic Recent Developments/Updates
7.6.6 Synlogic Competitive Strengths & Weaknesses
7.7 Enterome BioScience
7.7.1 Enterome BioScience Details
7.7.2 Enterome BioScience Major Business
7.7.3 Enterome BioScience Microbiome Therapeutics Product and Services
7.7.4 Enterome BioScience Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.7.5 Enterome BioScience Recent Developments/Updates
7.7.6 Enterome BioScience Competitive Strengths & Weaknesses
7.8 4D Pharma
7.8.1 4D Pharma Details
7.8.2 4D Pharma Major Business
7.8.3 4D Pharma Microbiome Therapeutics Product and Services
7.8.4 4D Pharma Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.8.5 4D Pharma Recent Developments/Updates
7.8.6 4D Pharma Competitive Strengths & Weaknesses
7.9 Second Genome
7.9.1 Second Genome Details
7.9.2 Second Genome Major Business
7.9.3 Second Genome Microbiome Therapeutics Product and Services
7.9.4 Second Genome Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.9.5 Second Genome Recent Developments/Updates
7.9.6 Second Genome Competitive Strengths & Weaknesses
7.10 Ferring
7.10.1 Ferring Details
7.10.2 Ferring Major Business
7.10.3 Ferring Microbiome Therapeutics Product and Services
7.10.4 Ferring Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.10.5 Ferring Recent Developments/Updates
7.10.6 Ferring Competitive Strengths & Weaknesses
7.11 C3 Jian
7.11.1 C3 Jian Details
7.11.2 C3 Jian Major Business
7.11.3 C3 Jian Microbiome Therapeutics Product and Services
7.11.4 C3 Jian Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.11.5 C3 Jian Recent Developments/Updates
7.11.6 C3 Jian Competitive Strengths & Weaknesses
7.12 Rebiotix
7.12.1 Rebiotix Details
7.12.2 Rebiotix Major Business
7.12.3 Rebiotix Microbiome Therapeutics Product and Services
7.12.4 Rebiotix Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.12.5 Rebiotix Recent Developments/Updates
7.12.6 Rebiotix Competitive Strengths & Weaknesses
7.13 MicroBiome Therapeutics LLC
7.13.1 MicroBiome Therapeutics LLC Details
7.13.2 MicroBiome Therapeutics LLC Major Business
7.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Product and Services
7.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.13.5 MicroBiome Therapeutics LLC Recent Developments/Updates
7.13.6 MicroBiome Therapeutics LLC Competitive Strengths & Weaknesses
7.14 Metabiomics
7.14.1 Metabiomics Details
7.14.2 Metabiomics Major Business
7.14.3 Metabiomics Microbiome Therapeutics Product and Services
7.14.4 Metabiomics Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.14.5 Metabiomics Recent Developments/Updates
7.14.6 Metabiomics Competitive Strengths & Weaknesses
7.15 Ritter Pharmaceuticals
7.15.1 Ritter Pharmaceuticals Details
7.15.2 Ritter Pharmaceuticals Major Business
7.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Product and Services
7.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.15.5 Ritter Pharmaceuticals Recent Developments/Updates
7.15.6 Ritter Pharmaceuticals Competitive Strengths & Weaknesses
7.16 Symberix
7.16.1 Symberix Details
7.16.2 Symberix Major Business
7.16.3 Symberix Microbiome Therapeutics Product and Services
7.16.4 Symberix Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.16.5 Symberix Recent Developments/Updates
7.16.6 Symberix Competitive Strengths & Weaknesses
7.17 OpenBiome
7.17.1 OpenBiome Details
7.17.2 OpenBiome Major Business
7.17.3 OpenBiome Microbiome Therapeutics Product and Services
7.17.4 OpenBiome Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.17.5 OpenBiome Recent Developments/Updates
7.17.6 OpenBiome Competitive Strengths & Weaknesses
7.18 Azitra
7.18.1 Azitra Details
7.18.2 Azitra Major Business
7.18.3 Azitra Microbiome Therapeutics Product and Services
7.18.4 Azitra Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.18.5 Azitra Recent Developments/Updates
7.18.6 Azitra Competitive Strengths & Weaknesses
7.19 Symbiotix Biotherapies
7.19.1 Symbiotix Biotherapies Details
7.19.2 Symbiotix Biotherapies Major Business
7.19.3 Symbiotix Biotherapies Microbiome Therapeutics Product and Services
7.19.4 Symbiotix Biotherapies Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.19.5 Symbiotix Biotherapies Recent Developments/Updates
7.19.6 Symbiotix Biotherapies Competitive Strengths & Weaknesses
7.20 Vedanta Biosciences
7.20.1 Vedanta Biosciences Details
7.20.2 Vedanta Biosciences Major Business
7.20.3 Vedanta Biosciences Microbiome Therapeutics Product and Services
7.20.4 Vedanta Biosciences Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.20.5 Vedanta Biosciences Recent Developments/Updates
7.20.6 Vedanta Biosciences Competitive Strengths & Weaknesses
7.21 Metabogen
7.21.1 Metabogen Details
7.21.2 Metabogen Major Business
7.21.3 Metabogen Microbiome Therapeutics Product and Services
7.21.4 Metabogen Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
7.21.5 Metabogen Recent Developments/Updates
7.21.6 Metabogen Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Microbiome Therapeutics Industry Chain
8.2 Microbiome Therapeutics Upstream Analysis
8.3 Microbiome Therapeutics Midstream Analysis
8.4 Microbiome Therapeutics Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Microbiome Therapeutics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Microbiome Therapeutics Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Microbiome Therapeutics Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Microbiome Therapeutics Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Microbiome Therapeutics Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Microbiome Therapeutics Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Microbiome Therapeutics Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Microbiome Therapeutics Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Microbiome Therapeutics Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Microbiome Therapeutics Players in 2025
Table 12. World Microbiome Therapeutics Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Microbiome Therapeutics Company Evaluation Quadrant
Table 14. Head Office of Key Microbiome Therapeutics Players
Table 15. Microbiome Therapeutics Market: Company Product Type Footprint
Table 16. Microbiome Therapeutics Market: Company Product Application Footprint
Table 17. Microbiome Therapeutics Mergers & Acquisitions Activity
Table 18. United States VS China Microbiome Therapeutics Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Microbiome Therapeutics Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Microbiome Therapeutics Companies, Headquarters (States, Country)
Table 21. United States Based Companies Microbiome Therapeutics Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Microbiome Therapeutics Revenue Market Share (2021-2026)
Table 23. China Based Microbiome Therapeutics Companies, Headquarters (Province, Country)
Table 24. China Based Companies Microbiome Therapeutics Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Microbiome Therapeutics Revenue Market Share (2021-2026)
Table 26. Rest of World Based Microbiome Therapeutics Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Microbiome Therapeutics Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Microbiome Therapeutics Revenue Market Share (2021-2026)
Table 29. World Microbiome Therapeutics Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Microbiome Therapeutics Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Microbiome Therapeutics Market Size by Type (2027-2032) & (USD Million)
Table 32. World Microbiome Therapeutics Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 33. World Microbiome Therapeutics Market Size by Application (2021-2026) & (USD Million)
Table 34. World Microbiome Therapeutics Market Size by Application (2027-2032) & (USD Million)
Table 35. Seres Therapeutics Basic Information, Manufacturing Base and Competitors
Table 36. Seres Therapeutics Major Business
Table 37. Seres Therapeutics Microbiome Therapeutics Product and Services
Table 38. Seres Therapeutics Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 39. Seres Therapeutics Recent Developments/Updates
Table 40. Seres Therapeutics Competitive Strengths & Weaknesses
Table 41. Assembly Biosciences Basic Information, Manufacturing Base and Competitors
Table 42. Assembly Biosciences Major Business
Table 43. Assembly Biosciences Microbiome Therapeutics Product and Services
Table 44. Assembly Biosciences Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Assembly Biosciences Recent Developments/Updates
Table 46. Assembly Biosciences Competitive Strengths & Weaknesses
Table 47. Synthetic Biologics Basic Information, Manufacturing Base and Competitors
Table 48. Synthetic Biologics Major Business
Table 49. Synthetic Biologics Microbiome Therapeutics Product and Services
Table 50. Synthetic Biologics Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Synthetic Biologics Recent Developments/Updates
Table 52. Synthetic Biologics Competitive Strengths & Weaknesses
Table 53. Finch Therapeutics Basic Information, Manufacturing Base and Competitors
Table 54. Finch Therapeutics Major Business
Table 55. Finch Therapeutics Microbiome Therapeutics Product and Services
Table 56. Finch Therapeutics Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Finch Therapeutics Recent Developments/Updates
Table 58. Finch Therapeutics Competitive Strengths & Weaknesses
Table 59. PureTech Basic Information, Manufacturing Base and Competitors
Table 60. PureTech Major Business
Table 61. PureTech Microbiome Therapeutics Product and Services
Table 62. PureTech Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. PureTech Recent Developments/Updates
Table 64. PureTech Competitive Strengths & Weaknesses
Table 65. Synlogic Basic Information, Manufacturing Base and Competitors
Table 66. Synlogic Major Business
Table 67. Synlogic Microbiome Therapeutics Product and Services
Table 68. Synlogic Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Synlogic Recent Developments/Updates
Table 70. Synlogic Competitive Strengths & Weaknesses
Table 71. Enterome BioScience Basic Information, Manufacturing Base and Competitors
Table 72. Enterome BioScience Major Business
Table 73. Enterome BioScience Microbiome Therapeutics Product and Services
Table 74. Enterome BioScience Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Enterome BioScience Recent Developments/Updates
Table 76. Enterome BioScience Competitive Strengths & Weaknesses
Table 77. 4D Pharma Basic Information, Manufacturing Base and Competitors
Table 78. 4D Pharma Major Business
Table 79. 4D Pharma Microbiome Therapeutics Product and Services
Table 80. 4D Pharma Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. 4D Pharma Recent Developments/Updates
Table 82. 4D Pharma Competitive Strengths & Weaknesses
Table 83. Second Genome Basic Information, Manufacturing Base and Competitors
Table 84. Second Genome Major Business
Table 85. Second Genome Microbiome Therapeutics Product and Services
Table 86. Second Genome Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Second Genome Recent Developments/Updates
Table 88. Second Genome Competitive Strengths & Weaknesses
Table 89. Ferring Basic Information, Manufacturing Base and Competitors
Table 90. Ferring Major Business
Table 91. Ferring Microbiome Therapeutics Product and Services
Table 92. Ferring Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Ferring Recent Developments/Updates
Table 94. Ferring Competitive Strengths & Weaknesses
Table 95. C3 Jian Basic Information, Manufacturing Base and Competitors
Table 96. C3 Jian Major Business
Table 97. C3 Jian Microbiome Therapeutics Product and Services
Table 98. C3 Jian Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. C3 Jian Recent Developments/Updates
Table 100. C3 Jian Competitive Strengths & Weaknesses
Table 101. Rebiotix Basic Information, Manufacturing Base and Competitors
Table 102. Rebiotix Major Business
Table 103. Rebiotix Microbiome Therapeutics Product and Services
Table 104. Rebiotix Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Rebiotix Recent Developments/Updates
Table 106. Rebiotix Competitive Strengths & Weaknesses
Table 107. MicroBiome Therapeutics LLC Basic Information, Manufacturing Base and Competitors
Table 108. MicroBiome Therapeutics LLC Major Business
Table 109. MicroBiome Therapeutics LLC Microbiome Therapeutics Product and Services
Table 110. MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. MicroBiome Therapeutics LLC Recent Developments/Updates
Table 112. MicroBiome Therapeutics LLC Competitive Strengths & Weaknesses
Table 113. Metabiomics Basic Information, Manufacturing Base and Competitors
Table 114. Metabiomics Major Business
Table 115. Metabiomics Microbiome Therapeutics Product and Services
Table 116. Metabiomics Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Metabiomics Recent Developments/Updates
Table 118. Metabiomics Competitive Strengths & Weaknesses
Table 119. Ritter Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 120. Ritter Pharmaceuticals Major Business
Table 121. Ritter Pharmaceuticals Microbiome Therapeutics Product and Services
Table 122. Ritter Pharmaceuticals Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Ritter Pharmaceuticals Recent Developments/Updates
Table 124. Ritter Pharmaceuticals Competitive Strengths & Weaknesses
Table 125. Symberix Basic Information, Manufacturing Base and Competitors
Table 126. Symberix Major Business
Table 127. Symberix Microbiome Therapeutics Product and Services
Table 128. Symberix Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Symberix Recent Developments/Updates
Table 130. Symberix Competitive Strengths & Weaknesses
Table 131. OpenBiome Basic Information, Manufacturing Base and Competitors
Table 132. OpenBiome Major Business
Table 133. OpenBiome Microbiome Therapeutics Product and Services
Table 134. OpenBiome Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. OpenBiome Recent Developments/Updates
Table 136. OpenBiome Competitive Strengths & Weaknesses
Table 137. Azitra Basic Information, Manufacturing Base and Competitors
Table 138. Azitra Major Business
Table 139. Azitra Microbiome Therapeutics Product and Services
Table 140. Azitra Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Azitra Recent Developments/Updates
Table 142. Azitra Competitive Strengths & Weaknesses
Table 143. Symbiotix Biotherapies Basic Information, Manufacturing Base and Competitors
Table 144. Symbiotix Biotherapies Major Business
Table 145. Symbiotix Biotherapies Microbiome Therapeutics Product and Services
Table 146. Symbiotix Biotherapies Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Symbiotix Biotherapies Recent Developments/Updates
Table 148. Symbiotix Biotherapies Competitive Strengths & Weaknesses
Table 149. Vedanta Biosciences Basic Information, Manufacturing Base and Competitors
Table 150. Vedanta Biosciences Major Business
Table 151. Vedanta Biosciences Microbiome Therapeutics Product and Services
Table 152. Vedanta Biosciences Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. Vedanta Biosciences Recent Developments/Updates
Table 154. Vedanta Biosciences Competitive Strengths & Weaknesses
Table 155. Metabogen Basic Information, Manufacturing Base and Competitors
Table 156. Metabogen Major Business
Table 157. Metabogen Microbiome Therapeutics Product and Services
Table 158. Metabogen Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. Metabogen Recent Developments/Updates
Table 160. Metabogen Competitive Strengths & Weaknesses
Table 161. Global Key Players of Microbiome Therapeutics Upstream (Raw Materials)
Table 162. Global Microbiome Therapeutics Typical Customers
Table 1. World Microbiome Therapeutics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Microbiome Therapeutics Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Microbiome Therapeutics Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Microbiome Therapeutics Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Microbiome Therapeutics Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Microbiome Therapeutics Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Microbiome Therapeutics Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Microbiome Therapeutics Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Microbiome Therapeutics Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Microbiome Therapeutics Players in 2025
Table 12. World Microbiome Therapeutics Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Microbiome Therapeutics Company Evaluation Quadrant
Table 14. Head Office of Key Microbiome Therapeutics Players
Table 15. Microbiome Therapeutics Market: Company Product Type Footprint
Table 16. Microbiome Therapeutics Market: Company Product Application Footprint
Table 17. Microbiome Therapeutics Mergers & Acquisitions Activity
Table 18. United States VS China Microbiome Therapeutics Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Microbiome Therapeutics Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Microbiome Therapeutics Companies, Headquarters (States, Country)
Table 21. United States Based Companies Microbiome Therapeutics Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Microbiome Therapeutics Revenue Market Share (2021-2026)
Table 23. China Based Microbiome Therapeutics Companies, Headquarters (Province, Country)
Table 24. China Based Companies Microbiome Therapeutics Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Microbiome Therapeutics Revenue Market Share (2021-2026)
Table 26. Rest of World Based Microbiome Therapeutics Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Microbiome Therapeutics Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Microbiome Therapeutics Revenue Market Share (2021-2026)
Table 29. World Microbiome Therapeutics Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Microbiome Therapeutics Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Microbiome Therapeutics Market Size by Type (2027-2032) & (USD Million)
Table 32. World Microbiome Therapeutics Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 33. World Microbiome Therapeutics Market Size by Application (2021-2026) & (USD Million)
Table 34. World Microbiome Therapeutics Market Size by Application (2027-2032) & (USD Million)
Table 35. Seres Therapeutics Basic Information, Manufacturing Base and Competitors
Table 36. Seres Therapeutics Major Business
Table 37. Seres Therapeutics Microbiome Therapeutics Product and Services
Table 38. Seres Therapeutics Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 39. Seres Therapeutics Recent Developments/Updates
Table 40. Seres Therapeutics Competitive Strengths & Weaknesses
Table 41. Assembly Biosciences Basic Information, Manufacturing Base and Competitors
Table 42. Assembly Biosciences Major Business
Table 43. Assembly Biosciences Microbiome Therapeutics Product and Services
Table 44. Assembly Biosciences Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Assembly Biosciences Recent Developments/Updates
Table 46. Assembly Biosciences Competitive Strengths & Weaknesses
Table 47. Synthetic Biologics Basic Information, Manufacturing Base and Competitors
Table 48. Synthetic Biologics Major Business
Table 49. Synthetic Biologics Microbiome Therapeutics Product and Services
Table 50. Synthetic Biologics Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Synthetic Biologics Recent Developments/Updates
Table 52. Synthetic Biologics Competitive Strengths & Weaknesses
Table 53. Finch Therapeutics Basic Information, Manufacturing Base and Competitors
Table 54. Finch Therapeutics Major Business
Table 55. Finch Therapeutics Microbiome Therapeutics Product and Services
Table 56. Finch Therapeutics Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Finch Therapeutics Recent Developments/Updates
Table 58. Finch Therapeutics Competitive Strengths & Weaknesses
Table 59. PureTech Basic Information, Manufacturing Base and Competitors
Table 60. PureTech Major Business
Table 61. PureTech Microbiome Therapeutics Product and Services
Table 62. PureTech Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. PureTech Recent Developments/Updates
Table 64. PureTech Competitive Strengths & Weaknesses
Table 65. Synlogic Basic Information, Manufacturing Base and Competitors
Table 66. Synlogic Major Business
Table 67. Synlogic Microbiome Therapeutics Product and Services
Table 68. Synlogic Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Synlogic Recent Developments/Updates
Table 70. Synlogic Competitive Strengths & Weaknesses
Table 71. Enterome BioScience Basic Information, Manufacturing Base and Competitors
Table 72. Enterome BioScience Major Business
Table 73. Enterome BioScience Microbiome Therapeutics Product and Services
Table 74. Enterome BioScience Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Enterome BioScience Recent Developments/Updates
Table 76. Enterome BioScience Competitive Strengths & Weaknesses
Table 77. 4D Pharma Basic Information, Manufacturing Base and Competitors
Table 78. 4D Pharma Major Business
Table 79. 4D Pharma Microbiome Therapeutics Product and Services
Table 80. 4D Pharma Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. 4D Pharma Recent Developments/Updates
Table 82. 4D Pharma Competitive Strengths & Weaknesses
Table 83. Second Genome Basic Information, Manufacturing Base and Competitors
Table 84. Second Genome Major Business
Table 85. Second Genome Microbiome Therapeutics Product and Services
Table 86. Second Genome Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Second Genome Recent Developments/Updates
Table 88. Second Genome Competitive Strengths & Weaknesses
Table 89. Ferring Basic Information, Manufacturing Base and Competitors
Table 90. Ferring Major Business
Table 91. Ferring Microbiome Therapeutics Product and Services
Table 92. Ferring Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Ferring Recent Developments/Updates
Table 94. Ferring Competitive Strengths & Weaknesses
Table 95. C3 Jian Basic Information, Manufacturing Base and Competitors
Table 96. C3 Jian Major Business
Table 97. C3 Jian Microbiome Therapeutics Product and Services
Table 98. C3 Jian Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. C3 Jian Recent Developments/Updates
Table 100. C3 Jian Competitive Strengths & Weaknesses
Table 101. Rebiotix Basic Information, Manufacturing Base and Competitors
Table 102. Rebiotix Major Business
Table 103. Rebiotix Microbiome Therapeutics Product and Services
Table 104. Rebiotix Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Rebiotix Recent Developments/Updates
Table 106. Rebiotix Competitive Strengths & Weaknesses
Table 107. MicroBiome Therapeutics LLC Basic Information, Manufacturing Base and Competitors
Table 108. MicroBiome Therapeutics LLC Major Business
Table 109. MicroBiome Therapeutics LLC Microbiome Therapeutics Product and Services
Table 110. MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. MicroBiome Therapeutics LLC Recent Developments/Updates
Table 112. MicroBiome Therapeutics LLC Competitive Strengths & Weaknesses
Table 113. Metabiomics Basic Information, Manufacturing Base and Competitors
Table 114. Metabiomics Major Business
Table 115. Metabiomics Microbiome Therapeutics Product and Services
Table 116. Metabiomics Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Metabiomics Recent Developments/Updates
Table 118. Metabiomics Competitive Strengths & Weaknesses
Table 119. Ritter Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 120. Ritter Pharmaceuticals Major Business
Table 121. Ritter Pharmaceuticals Microbiome Therapeutics Product and Services
Table 122. Ritter Pharmaceuticals Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Ritter Pharmaceuticals Recent Developments/Updates
Table 124. Ritter Pharmaceuticals Competitive Strengths & Weaknesses
Table 125. Symberix Basic Information, Manufacturing Base and Competitors
Table 126. Symberix Major Business
Table 127. Symberix Microbiome Therapeutics Product and Services
Table 128. Symberix Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Symberix Recent Developments/Updates
Table 130. Symberix Competitive Strengths & Weaknesses
Table 131. OpenBiome Basic Information, Manufacturing Base and Competitors
Table 132. OpenBiome Major Business
Table 133. OpenBiome Microbiome Therapeutics Product and Services
Table 134. OpenBiome Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. OpenBiome Recent Developments/Updates
Table 136. OpenBiome Competitive Strengths & Weaknesses
Table 137. Azitra Basic Information, Manufacturing Base and Competitors
Table 138. Azitra Major Business
Table 139. Azitra Microbiome Therapeutics Product and Services
Table 140. Azitra Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Azitra Recent Developments/Updates
Table 142. Azitra Competitive Strengths & Weaknesses
Table 143. Symbiotix Biotherapies Basic Information, Manufacturing Base and Competitors
Table 144. Symbiotix Biotherapies Major Business
Table 145. Symbiotix Biotherapies Microbiome Therapeutics Product and Services
Table 146. Symbiotix Biotherapies Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Symbiotix Biotherapies Recent Developments/Updates
Table 148. Symbiotix Biotherapies Competitive Strengths & Weaknesses
Table 149. Vedanta Biosciences Basic Information, Manufacturing Base and Competitors
Table 150. Vedanta Biosciences Major Business
Table 151. Vedanta Biosciences Microbiome Therapeutics Product and Services
Table 152. Vedanta Biosciences Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. Vedanta Biosciences Recent Developments/Updates
Table 154. Vedanta Biosciences Competitive Strengths & Weaknesses
Table 155. Metabogen Basic Information, Manufacturing Base and Competitors
Table 156. Metabogen Major Business
Table 157. Metabogen Microbiome Therapeutics Product and Services
Table 158. Metabogen Microbiome Therapeutics Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. Metabogen Recent Developments/Updates
Table 160. Metabogen Competitive Strengths & Weaknesses
Table 161. Global Key Players of Microbiome Therapeutics Upstream (Raw Materials)
Table 162. Global Microbiome Therapeutics Typical Customers
LIST OF FIGURES
Figure 1. Microbiome Therapeutics Picture
Figure 2. World Microbiome Therapeutics Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Microbiome Therapeutics Total Revenue (2021-2032) & (USD Million)
Figure 4. World Microbiome Therapeutics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Microbiome Therapeutics Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Microbiome Therapeutics Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Microbiome Therapeutics Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Microbiome Therapeutics Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Microbiome Therapeutics Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Microbiome Therapeutics Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Microbiome Therapeutics Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Microbiome Therapeutics Revenue (2021-2032) & (USD Million)
Figure 13. Microbiome Therapeutics Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Microbiome Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 16. World Microbiome Therapeutics Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Microbiome Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 18. China Microbiome Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Microbiome Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Microbiome Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Microbiome Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Microbiome Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 23. India Microbiome Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Microbiome Therapeutics by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Microbiome Therapeutics Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Microbiome Therapeutics Markets in 2025
Figure 27. United States VS China: Microbiome Therapeutics Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Microbiome Therapeutics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Microbiome Therapeutics Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Microbiome Therapeutics Market Size Market Share by Type in 2025
Figure 31. Upper GIT
Figure 32. Lower GIT
Figure 33. World Microbiome Therapeutics Market Size Market Share by Type (2021-2032)
Figure 34. World Microbiome Therapeutics Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 35. World Microbiome Therapeutics Market Size Market Share by Application in 2025
Figure 36. C. difficile Infection (CDI)
Figure 37. Inflammatory Bowel Disease (IBD)
Figure 38. Orphan Drug
Figure 39. Immuno-oncology
Figure 40. Others
Figure 41. World Microbiome Therapeutics Market Size Market Share by Application (2021-2032)
Figure 42. Microbiome Therapeutics Industrial Chain
Figure 43. Methodology
Figure 44. Research Process and Data Source
Figure 1. Microbiome Therapeutics Picture
Figure 2. World Microbiome Therapeutics Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Microbiome Therapeutics Total Revenue (2021-2032) & (USD Million)
Figure 4. World Microbiome Therapeutics Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Microbiome Therapeutics Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Microbiome Therapeutics Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Microbiome Therapeutics Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Microbiome Therapeutics Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Microbiome Therapeutics Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Microbiome Therapeutics Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Microbiome Therapeutics Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Microbiome Therapeutics Revenue (2021-2032) & (USD Million)
Figure 13. Microbiome Therapeutics Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Microbiome Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 16. World Microbiome Therapeutics Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Microbiome Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 18. China Microbiome Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Microbiome Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Microbiome Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Microbiome Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Microbiome Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 23. India Microbiome Therapeutics Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Microbiome Therapeutics by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Microbiome Therapeutics Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Microbiome Therapeutics Markets in 2025
Figure 27. United States VS China: Microbiome Therapeutics Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Microbiome Therapeutics Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Microbiome Therapeutics Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Microbiome Therapeutics Market Size Market Share by Type in 2025
Figure 31. Upper GIT
Figure 32. Lower GIT
Figure 33. World Microbiome Therapeutics Market Size Market Share by Type (2021-2032)
Figure 34. World Microbiome Therapeutics Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 35. World Microbiome Therapeutics Market Size Market Share by Application in 2025
Figure 36. C. difficile Infection (CDI)
Figure 37. Inflammatory Bowel Disease (IBD)
Figure 38. Orphan Drug
Figure 39. Immuno-oncology
Figure 40. Others
Figure 41. World Microbiome Therapeutics Market Size Market Share by Application (2021-2032)
Figure 42. Microbiome Therapeutics Industrial Chain
Figure 43. Methodology
Figure 44. Research Process and Data Source
